Diquafosol tetrasodium
Phase 3Small molecule
Merck & Co.Diquafosol tetrasodium is one of 34 small molecule programs targeting Eye Disease. It is currently in Phase 3.
1
Indications
6
Total Trials
0
Active Trials
33
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
200 competitors in Eye Disease
#DrugCompanyPhaseTrials
1Chantix
PfizerPhase 3
Bayer Aspirin
BayerPhase 3
Aquasol E
NNational Eye Institute (NEI)
Phase 3
CF101
CCan-Fite BioPharma
Phase 3
Carboxymethylcellulose
AbbViePhase 3
Refresh Plus
AbbViePhase 3
Cenegermin
DDompé Farmaceutici S.p.A
Phase 3
Csa
ZZhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.
Phase 3
REFRESH LIQUIGEL
AbbViePhase 3
Refresh Optive
AbbViePhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Eye Disease3 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Diquafosol tetrasodium. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company